The company is dedicating a significant portion of its revenue, approximately 18% of sales, to R&D, with a primary focus on investments in transcatheter structural heart programs for mitral, aortic, and tricuspid therapies.
Filing excerpt
Research and development spending increased approximately 2% year over year, representing approximately 18% of 2025 sales. This increase was primarily the result of significant investments in our transcatheter structural heart programs, including an increase in clinical research for our mitral, aortic, and tricuspid therapies.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-10kcapexIncreaseGet every 10-K signal for Edwards Lifesciences and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Edwards Lifesciences this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/8da8ae97-0145-45f6-9668-cdeed68afe5f returns this record as JSON. POST /v1/companies/enrich returns every signal for edwards.com.
{
"signal_id": "8da8ae97-0145-45f6-9668-cdeed68afe5f",
"signal_type": "sec-10k",
"signal_subtype": "capexIncrease",
"detected_at": "2026-03-03T05:54:08.55+00:00",
"company": {
"name": "Edwards Lifesciences",
"domain": "edwards.com"
},
"data": {
"detail": "The company is dedicating a significant portion of its revenue, approximately 18% of sales, to R&D, with a primary focus on investments in transcatheter structural heart programs for mitral, aortic, and tricuspid therapies.",
"metrics": {
"pct": 0.18,
"timeframe": "current_year",
"pct_context": "of 2025 sales invested in R&D"
},
"summary": "Investing 18% of total 2025 sales into R&D for structural heart programs.",
"excerpts": "Research and development spending increased approximately 2% year over year, representing approximately 18% of 2025 sales. This increase was primarily the result of significant investments in our transcatheter structural heart programs, including an increase in clinical research for our mitral, aortic, and tricuspid therapies.",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/ew-20251231.htm",
"filing_date": "2026-02-25",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Budget available",
"signal_category": "financial"
}
}
curl https://signals.autobound.ai/v1/signals/8da8ae97-0145-45f6-9668-cdeed68afe5f \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"edwards.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.